Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Citius Pharmaceuticals initiated with a Buy at Maxim » 08:39
11/30/21
11/30
08:39
11/30/21
08:39
CTXR

Citius Pharmaceuticals

$1.62 /

-0.07 (-4.14%)

Maxim analyst Michael…

Maxim analyst Michael Okunewitch initiated coverage of Citius Pharmaceuticals with a Buy rating and $4 price target. The analyst cites the company's upcoming two pivotal readouts in oncology and infectious disease. Okunewitch adds that with about $70M in cash, Citius is funded through pivotal readouts set for the first half of 2022, which represent potentially "transformative catalysts". The analyst further states that both assets address areas of high unmet need, and have commercial synergies due to a shared target customer.

ShowHide Related Items >><<
CTXR Citius Pharmaceuticals
$1.62 /

-0.07 (-4.14%)

CTXR Citius Pharmaceuticals
$1.62 /

-0.07 (-4.14%)

11/30/21 Maxim
Citius Pharmaceuticals initiated with a Buy at Maxim
CTXR Citius Pharmaceuticals
$1.62 /

-0.07 (-4.14%)

CTXR Citius Pharmaceuticals
$1.62 /

-0.07 (-4.14%)

CTXR Citius Pharmaceuticals
$1.62 /

-0.07 (-4.14%)

Initiation
Citius Pharmaceuticals initiated with a Buy at Maxim » 08:23
11/30/21
11/30
08:23
11/30/21
08:23
CTXR

Citius Pharmaceuticals

$1.62 /

-0.07 (-4.14%)

Maxim analyst Michael…

Maxim analyst Michael Okunewitch initiated coverage of Citius Pharmaceuticals with a Buy rating and $4 price target.

ShowHide Related Items >><<
CTXR Citius Pharmaceuticals
$1.62 /

-0.07 (-4.14%)

CTXR Citius Pharmaceuticals
$1.62 /

-0.07 (-4.14%)

CTXR Citius Pharmaceuticals
$1.62 /

-0.07 (-4.14%)

CTXR Citius Pharmaceuticals
$1.62 /

-0.07 (-4.14%)

Over a week ago
Conference/Events
Citius Pharmaceuticals to hold a key opinion leader webcast » 11:25
11/11/21
11/11
11:25
11/11/21
11:25
CTXR

Citius Pharmaceuticals

$1.83 /

+0.015 (+0.83%)

Management provides an…

Management provides an update on the potential of Citius's Mino-Lok treatment to salvage Central Venous Catheters in patients with central line associated blood stream infections (CLABSI) on a Key Opinion Leader webcast to be held on November 11 at 11:30 am. Webcast Link

ShowHide Related Items >><<
CTXR Citius Pharmaceuticals
$1.83 /

+0.015 (+0.83%)

CTXR Citius Pharmaceuticals
$1.83 /

+0.015 (+0.83%)

CTXR Citius Pharmaceuticals
$1.83 /

+0.015 (+0.83%)

CTXR Citius Pharmaceuticals
$1.83 /

+0.015 (+0.83%)

Conference/Events
Citius Pharmaceuticals to hold a key opinion leader webcast » 10:11
11/11/21
11/11
10:11
11/11/21
10:11
CTXR

Citius Pharmaceuticals

$1.87 /

+0.055 (+3.03%)

Management provides an…

Management provides an update on the potential of Citius's Mino-Lok treatment to salvage Central Venous Catheters in patients with central line associated blood stream infections (CLABSI) on a Key Opinion Leader webcast to be held on November 11 at 11:30 am. Webcast Link

ShowHide Related Items >><<
CTXR Citius Pharmaceuticals
$1.87 /

+0.055 (+3.03%)

CTXR Citius Pharmaceuticals
$1.87 /

+0.055 (+3.03%)

CTXR Citius Pharmaceuticals
$1.87 /

+0.055 (+3.03%)

CTXR Citius Pharmaceuticals
$1.87 /

+0.055 (+3.03%)

Over a month ago
Conference/Events
Citius Pharmaceuticals to hold a conference call » 08:25
10/20/21
10/20
08:25
10/20/21
08:25
CTXR

Citius Pharmaceuticals

$2.11 /

+0.015 (+0.72%)

Executive Chairman Mazur,…

Executive Chairman Mazur, CEO Holubiak, CFO Bartushak and CMO Czuczman discuss the Company's strategy and the late Phase 3 Cancer Immunotherapy I/ONTAK acquisition on a conference call to be held on October 20 at 8:30 am. Webcast Link

ShowHide Related Items >><<
CTXR Citius Pharmaceuticals
$2.11 /

+0.015 (+0.72%)

CTXR Citius Pharmaceuticals
$2.11 /

+0.015 (+0.72%)

CTXR Citius Pharmaceuticals
$2.11 /

+0.015 (+0.72%)

CTXR Citius Pharmaceuticals
$2.11 /

+0.015 (+0.72%)

Conference/Events
Citius Pharmaceuticals to hold a conference call » 04:55
10/20/21
10/20
04:55
10/20/21
04:55
CTXR

Citius Pharmaceuticals

$2.11 /

+0.015 (+0.72%)

Executive Chairman Mazur,…

Executive Chairman Mazur, CEO Holubiak, CFO Bartushak and CMO Czuczman discuss the Company's strategy and the late Phase 3 Cancer Immunotherapy I/ONTAK acquisition on a conference call to be held on October 20 at 8:30 am. Webcast Link

ShowHide Related Items >><<
CTXR Citius Pharmaceuticals
$2.11 /

+0.015 (+0.72%)

CTXR Citius Pharmaceuticals
$2.11 /

+0.015 (+0.72%)

CTXR Citius Pharmaceuticals
$2.11 /

+0.015 (+0.72%)

CTXR Citius Pharmaceuticals
$2.11 /

+0.015 (+0.72%)

Conference/Events
Citius Pharmaceuticals to hold a conference call » 13:51
10/13/21
10/13
13:51
10/13/21
13:51
CTXR

Citius Pharmaceuticals

$2.02 /

+0.01 (+0.50%)

Executive Chairman Mazur,…

Executive Chairman Mazur, CEO Holubiak, CFO Bartushak and CMO Czuczman discuss the Company's strategy and the late Phase 3 Cancer Immunotherapy I/ONTAK acquisition on a conference call to be held on October 20 at 8:30 am. Webcast Link

ShowHide Related Items >><<
CTXR Citius Pharmaceuticals
$2.02 /

+0.01 (+0.50%)

CTXR Citius Pharmaceuticals
$2.02 /

+0.01 (+0.50%)

CTXR Citius Pharmaceuticals
$2.02 /

+0.01 (+0.50%)

CTXR Citius Pharmaceuticals
$2.02 /

+0.01 (+0.50%)

Hot Stocks
Citius Pharmaceuticals acquires Dr. Reddy's license for E7777 » 07:47
09/07/21
09/07
07:47
09/07/21
07:47
CTXR

Citius Pharmaceuticals

$2.11 /

-0.03 (-1.41%)

, RDY

Dr. Reddy's

$67.08 /

+0.405 (+0.61%)

, ESALY

Eisai

$85.10 /

+2.12 (+2.55%)

Citius Pharmaceuticals…

Citius Pharmaceuticals (CTXR) announced that it has entered into a definitive agreement with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories (RDY), to acquire its exclusive license of E7777, a late-stage oncology immunotherapy for the treatment of CTCL. E7777, an engineered IL-2-diphtheria toxin fusion protein, is an improved formulation of oncology agent, ONTAK, which was previously approved by the U.S. Food and Drug Administration for the treatment of patients with persistent or recurrent CTCL. The last patient in a trial of E7777 has been enrolled, and a biologics license application for E7777's first indication in CTCL is expected to be filed with the FDA by the end of 2022. Under the terms of this agreement, Citius will acquire Dr. Reddy's exclusive license of E7777 from Eisai (ESALY) and other related assets owned by Dr. Reddy's. Citius's exclusive license rights include rights to develop and commercialize E7777 in all markets except for Japan and certain parts of Asia. Additionally, Citius will retain an option on the right to develop and market the product in India. Eisai retains exclusive development and marketing rights for the agent in Japan and Asia. Dr. Reddy's will receive a $40M upfront payment and is entitled to up to $40M in development milestone payments related to CTCL approvals in the U.S. and other markets, up to $70M in development milestones for additional indications, as well as commercial milestone payments and low double-digit tiered royalties on net product sales. Eisai is to receive a $6M development milestone payment upon initial approval and additional commercial milestone payments related to the achievement of net product sales thresholds. Eisai will be responsible for completing the current CTCL clinical trial, and chemistry, manufacturing and controls activities through the filing of a BLA for E7777 with the U.S. Food and Drug Administration. Citius will be responsible for development costs associated with potential additional indications.

ShowHide Related Items >><<
RDY Dr. Reddy's
$67.08 /

+0.405 (+0.61%)

ESALY Eisai
$85.10 /

+2.12 (+2.55%)

CTXR Citius Pharmaceuticals
$2.11 /

-0.03 (-1.41%)

CTXR Citius Pharmaceuticals
$2.11 /

-0.03 (-1.41%)

RDY Dr. Reddy's
$67.08 /

+0.405 (+0.61%)

07/27/21 Credit Suisse
Dr. Reddy's downgraded to Neutral at Credit Suisse after Q1 report
07/27/21 Credit Suisse
Dr. Reddy's downgraded to Neutral from Outperform at Credit Suisse
02/03/21 Investec
Dr. Reddy's upgraded to Buy from Hold at Investec
02/02/21 Barclays
Dr. Reddy's upgraded to Overweight from Equal Weight at Barclays
ESALY Eisai
$85.10 /

+2.12 (+2.55%)

06/25/21 Morgan Stanley
Eisai downgraded to Equal Weight from Overweight at Morgan Stanley
06/17/21 JPMorgan
Eisai upgraded to Overweight from Neutral at JPMorgan
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
CTXR Citius Pharmaceuticals
$2.11 /

-0.03 (-1.41%)

RDY Dr. Reddy's
$67.08 /

+0.405 (+0.61%)

ESALY Eisai
$85.10 /

+2.12 (+2.55%)

ESALY Eisai
$85.10 /

+2.12 (+2.55%)

CTXR Citius Pharmaceuticals
$2.11 /

-0.03 (-1.41%)

CTXR Citius Pharmaceuticals
$2.11 /

-0.03 (-1.41%)

Over a quarter ago
Syndicate
Citius Pharmaceuticals files $150M mixed securities shelf  16:31
08/12/21
08/12
16:31
08/12/21
16:31
CTXR

Citius Pharmaceuticals

$1.84 /

+0.01 (+0.55%)

 
ShowHide Related Items >><<
CTXR Citius Pharmaceuticals
$1.84 /

+0.01 (+0.55%)

CTXR Citius Pharmaceuticals
$1.84 /

+0.01 (+0.55%)

CTXR Citius Pharmaceuticals
$1.84 /

+0.01 (+0.55%)

CTXR Citius Pharmaceuticals
$1.84 /

+0.01 (+0.55%)

Earnings
Citius Pharmaceuticals reports Q3 EPS (5c), consensus (6c)  16:31
08/12/21
08/12
16:31
08/12/21
16:31
CTXR

Citius Pharmaceuticals

$1.84 /

+0.01 (+0.55%)

 
ShowHide Related Items >><<
CTXR Citius Pharmaceuticals
$1.84 /

+0.01 (+0.55%)

CTXR Citius Pharmaceuticals
$1.84 /

+0.01 (+0.55%)

CTXR Citius Pharmaceuticals
$1.84 /

+0.01 (+0.55%)

CTXR Citius Pharmaceuticals
$1.84 /

+0.01 (+0.55%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.